This summary is based on the original article, which can be found here.
Cellipont Bioservices, a contract development and manufacturing organization (CDMO) specializing in cell therapy manufacturing, has entered into a strategic partnership with Xiogenix, a biotechnology leader in advanced manufacturing technologies. Announced on December 10, 2024, this collaboration enables Cellipont’s clients to access Xiogenix’s Ares™ X20 fill-and-finish system, a cutting-edge solution designed for cell and gene therapy production.
The Ares™ X20 system features precise temperature control, automated formulation, and high-throughput capabilities, processing multiple containers in under five minutes. This innovation enhances manufacturing efficiency and reliability, aligning with Cellipont’s commitment to adopting technologies that drive excellence in biopharmaceutical production.
“This partnership with Xiogenix marks another significant milestone for Cellipont Bioservices,” said Darren Head, CEO of Cellipont Bioservices. Rachel Bahr, CEO of Xiogenix, expressed enthusiasm for expanding access to the Ares™ X20 system and its potential to improve the biopharmaceutical industry.
The article also highlights Cellipont’s recent agreement with Mongoose Bio, a clinical-stage biopharmaceutical company focused on T-cell-based cancer therapies. Cellipont is manufacturing Mongoose Bio’s MGB-001 TCR-T cell therapy program, designed to target solid tumors. The partnership leverages Cellipont’s manufacturing expertise to advance promising therapies into the clinic and transform cancer treatment.
These developments underscore Cellipont’s strategic growth and dedication to advancing cell therapy manufacturing and innovation.